Search
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalLenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide and like thalidomide, lenalidomi...
Putrescine
go.drugbank.com/drugs/DB01917InvestigationalThese are compounds containing more than one amine group.
AOD9604
go.drugbank.com/drugs/DB06388ExperimentalAOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.
Alfaxalone
go.drugbank.com/drugs/DB11371ExperimentalVet approvedAlong with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin.
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for ...
Veglin
go.drugbank.com/drugs/DB05890ExperimentalVeglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.
Clocapramine
go.drugbank.com/drugs/DB09003ExperimentalClocapramine has been implicated in at least one strange death, including a suicide.
Ezetimibe
go.drugbank.com/drugs/DB00973ApprovedInvestigationalEzetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in ...
Norclozapine
go.drugbank.com/drugs/DB05766InvestigationalIt combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.